dose-adjusted epoch chemotherapy and rituximab (cd20+) in previously untreated aggressive non-hodgkin's lymphoma

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL); Primary Mediastinal Large B-cell Lymphoma; Burkitt Lymphoma; Anaplastic Large-Cell Lymphoma; Gray Zone Lymphoma

Summary: 5-drug combination chemotherapy with hematologic toxicity attenuation. etoposide phosphate, prednisone, vincristine sulfate (oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin)(epoch): etoposide, vp-16, nsc-141540; prednisone, pred, nsc-10023; vincristine, vcr, nsc-67574; cyclophosphamide, ctx, nsc-26271; doxorubicin, dox, nsc-123127; with granulocyte colony-stimulating factor (amgen), granulocyte colony-stimulating factor (g-csf), nsc-614629.

background: the treatment of the intermediate and aggressive non-hodgkin's lymphomas in adults and children commonly induces complete responses in a sizable fraction of the treated population, and about 2/3 of the complete responders appear to have prolonged disease-free survival. the present study assesses the activity and tolerability in previously untreated patients of a regimen of etoposide phosphate, prednisone, vincristine sulfate (oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin)(epoch) infusional chemotherapy given intensively with granulocyte colony-stimulating factor (g-csf) support. objectives: primary: assess complete response (cr) and progression-free survival (pfs) of dose-adjusted epoch-rituximab (da-epoch-r) with g-csf in aggressive b-cell lymphomas. eligibility: non-hodgkin's lymphomas in the following categories: mediastinal gray zone lymphoma (mgzl) and primary mediastinal b cell lymphoma (pmbl). patients greater than or equal to 12 years old. any stage for pmbl and mgzl. no prior systemic chemotherapy. human immunodeficiency virus (hiv) negative. design: this study will estimate the complete response rate of a group of previously untreated patients and the extent to which epoch infusional drug delivery accompanied by a hematopoietic growth factor can increase the dose intensity of treatment. patients receive prednisone orally for 5 days, a 96-hour infusion of vincristine, doxorubicin, and etoposide, and a bolus of cyclophosphamide on day 5. cycles are repeated every 21 days for a total of 6-8 cycles. patients with cluster of differentiation 20 (cd20) expressing tumors (i.e., mature b-cell lymphomas) will also receive rituximab, the humanized monoclonal antibody against the cd20 receptor on day 1 of each cycle. a total of 348 patients will be enrolled on this protocol.

Eligibility criteria:
* inclusion criteria: non-hodgkin's lymphomas in the following categories: mediastinal gray zone lymphoma and primary mediastinal b cell lymphoma. diagnosis confirmed by staff of the hematopathology section, laboratory of pathology, national cancer institute (nci). tissue blocks from patients treated in extramural sites must be forwarded to the nci for analysis of b-cell leukemia/lymphoma 2 (bcl-2) by immunohistochemistry (ihc) and other markers within 1 month of study entry. patients greater than or equal to 12 years old. stage and prognosis of patients: any stage for mediastinal gray zone lymphoma (mgzl) and primary mediastinal b-cell lymphoma (pmbl). no prior systemic chemotherapy. patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids and/or cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome). human immunodeficiency virus (hiv) negative. not pregnant or nursing. adequate major organ function \[in adults: serum creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than 60 ml/min; and in children serum creatinine (cr) less than or equal to age-adjusted normal (age 12 to 15 maximum serum creatinine 1.2 mg/dl and age greater than 15 maximum serum creatinine 1.5 mg/dl); bilirubin less than 1.5 mg/dl; absolute neutrophil count (anc) greater than 1,000 and platelets greater than 100,000) unless impairment is due to organ involvement by lymphoma or immune-mediated mechanism caused by lymphoma. no active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year. if multi-gated acquisition (muga) is obtained, the left ventricular ejection fraction (lvef) should exceed 40%. no other serious concomitant medical illnesses or uncontrolled active infection that would jeopardize the patient's ability to receive the regimen with reasonable safety. no history of unrelated (non-lymphomatous) neoplasms within past 5 years other than non-melanoma skin cancer or in-situ cancer. ability to give informed consent.

Keywords: primary mediastinal b-cell lymphoma cd20 + diffuse large b-cell lymphoma anaplastic large cell lymphoma de novo